Maine Medical Center

Dr. Corrigan brings over three decades of life sciences leadership experience to Silver Creek. SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused on the selective targeting of naturally-occurring growth factors to promote cell survival and growth, has appointed Mark Corrigan, MD, as President. Continue Reading (PRNewsfoto/SILVER CREEK PHARMACEUTICALS) "We are pleased to welcome Dr. Corrigan to lead Silver Creek through its next phase of growth," said Tim Throsby, Silver Creek's Chairman of the Board. "We are confident that Mark's deep experience in drug development and life sciences leadership will enable the company to continue to advance scp776 and our Smart Growth Factor™ platform, bringing us one step closer to achieving our mission of changing lives by rescuing cells from injury." "The elegance and innovation behind Silver Creek's Smart Growth Factor™ platform is very compelling, and the pre-clinical data around scp776 is equally impressive. I am excited to join the team at a time when the ARPEGGIO study is gaining momentum, and to help guide the organization through this much-anticipated data read-out," said Dr. Corrigan. Dr. Corrigan is an industry veteran with over three decades of life sciences leadership and drug development experience. Dr. Corrigan most recently served as CEO of Tremeau Pharmaceuticals, a non-opioid pain company that he co-founded. Dr. Corrigan previously served as CEO of Correvio Pharma Corp, leading their acquisition by Advanz Pharma in 2021. Prior to that, he served as Executive Vice President, Research and Development, at Sepracor. Prior to joining Sepracor, Dr. Corrigan spent 10 years with Pharmacia & Upjohn, culminating as Vice President of Global Clinical Research and Experimental Medicine. Dr. Corrigan serves as Chairman of the Board of Elios Therapeutics and as a member of the Board of Wave Life Sciences and Trevena Pharmaceuticals. Dr. Corrigan previously served on the Board of Cubist prior to its acquisition by Merck and on the Board of Avanir prior to its acquisition by Otsuka. Dr. Corrigan holds a B.A. and M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. About scp776 Scp776 is Silver Creek's lead investigational therapy. Scp776 is a first-in-class, targeted fusion protein that harnesses the cell survival function of insulin-like growth factor 1 (IGF-1). Scp776 is currently being evaluated in ARPEGGIO, a Phase II study for the treatment of acute ischemic stroke (NCT05585606). About ARPEGGIO ARPEGGIO (NCT05585606) is a randomized, placebo-controlled Phase II study evaluating the safety and neuroprotective capacity of scp776 in subjects undergoing endovascular thrombectomy for acute ischemic stroke. ARPEGGIO is actively enrolling subjects at multiple centers across the United States. For more information, please visit . About Silver Creek Pharmaceuticals Silver Creek is a clinical-stage biotechnology company headquartered in San Francisco, CA. Silver Creek's Smart Growth Factor™ technology enables the rapid development of targeted therapeutics with broad scope and applicability. Our lead asset, scp776, is a first-in-class, targeted fusion protein that harnesses the cell survival function of IGF-1. For more information about Silver Creek, please visit . Media Contact: Corey MacGregor VP, New Products Planning Silver Creek Pharmaceuticals [email protected] SOURCE Silver Creek Pharmaceuticals, Inc.

CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company’s Board of Directors, effective July 18 2023. “We are pleased to welcome Mark to Trevena’s Board of Directors,” said Carrie Bourdow, Trevena’s President and CEO. “Mark has over 30 years of experience in the life sciences industry and broad neuroscience expertise. He will be an invaluable member of the Board and guide to the management team as we continue to execute on our corporate strategy and advance our novel S1P receptor modulator, TRV045, for the potential treatment of epilepsy and chronic pain.” “This is a very exciting time for Trevena, a company with the proven ability to take a novel product from initial discovery through development, approval and launch,” said Dr. Corrigan. “Trevena has an innovative pipeline of wholly owned CNS assets, and I am particularly excited about the many near-term milestones, including data readouts from the two proof-of-concept studies for TRV045.” Dr. Corrigan is a highly successful pharmaceutical executive with more than 30 years of industry experience. Dr. Corrigan has served as Chief Executive Officer of Tremeau Pharmaceuticals, a pharmaceutical company that Dr. Corrigan co-founded, since January 2023. Dr. Corrigan has also served on the Board of Directors of Tremeau since April 2017. Prior to his appointment as CEO of Tremeau, Dr. Corrigan served as Chief Executive Officer of Correvio Pharma Corp, a specialty pharmaceutical company, and prior to that as President of Research & Development of Tremeau. Dr. Corrigan serves as Chairman of the Board of Directors of Elios Therapeutics and as a member of the Board of Directors of Nabriva Therapeutics and Wave Life Sciences. In addition, Dr. Corrigan is currently a visiting professor in the Department of Psychiatry at Brigham and Women’s Hospital in Boston, MA. Dr. Corrigan previously served on the Board of Directors of Cubist Pharmaceuticals, a hospital acute care focused company, prior to its approximately $9.5 billion acquisition by Merck. He also served as a member of the Board of Directors and Chair of the Scientific Advisory Committee of Avanir Pharmaceuticals, a CNS focused company, prior to its approximately $3.5 billion acquisition by Otsuka Pharmaceutical. Dr. Corrigan holds a B.A. and M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. About Trevena Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK® (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. For more information, please visit www.Trevena.com About TRV045 TRV045 is a novel, selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy. S1P receptors are located throughout the body, including the central nervous system, where they are believed to play a role in modulating neurotransmission and membrane excitability. Trevena's discovery efforts have identified a family of compounds that are highly selective for the S1P1 receptor. TRV045 reversed thermal hyperalgesia, a measure of neuropathic pain, in nonclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. TRV045 was not associated with lymphopenia and produced no changes in blood pressure, heart rate, or respiratory function at or above pharmacologically active doses in nonclinical studies. TRV045 is an investigational product and is not yet approved by the FDA. Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development and trials of its therapeutic candidates and approved product, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the status, timing, costs, results and interpretation of the Company’s clinical trials or any future trials of any of the Company’s investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company’s assessment of discussions with FDA; available funding; uncertainties related to the Company’s intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates and approved product; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law. For more information, please contact: Investor Contact: Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com(617) 430-7576 Company Contact: Bob YoderSVP and Chief Business OfficerTrevena, Inc.(610) 354-8840

WASHINGTON, June 21, 2023 /PRNewswire/ -- The National Resident Matching Program (NRMP) has chosen an outstanding group of candidates with a diverse set of backgrounds and experiences to join its 20-person Board of Directors. Their terms will begin July 1, 2023. "We're thrilled to welcome Dr. LaFemina, Dr. Mariano, Dr. Mosquera Vasquez, Ms. Adeyeri, and Mr. Ratna to the NRMP Board of Directors," said NRMP Board Chair Deborah Clements, MD. "Their experiences as learners, residents and fellows, and program directors will contribute greatly to the work of the NRMP and its pursuit of new strategic goals and initiatives to inform improvements to the transition to residency." Jennifer LaFemina, MD, FACS, is a surgical oncologist at the University of Massachusetts Memorial Healthcare (UMMHC) in Worcester and serves as the Program Director of General Surgery at the University of Massachusetts. She completed her General Surgery residency at Massachusetts General Hospital in Boston and her Surgical Oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York City. Dr. LaFemina currently serves as the UMMHC Chair of the Breast Program Leadership and Breast Surgical Lead at the University of Massachusetts in Worcester and in 2021 was accepted as an associate member of the Academy of Master Surgeon Educators. She has a strong commitment to surgical education and building resident readiness and competencies. Melissa Garrett Mariano, DO, is an internal medicine resident physician at Mount Auburn Hospital in Cambridge, Massachusetts. She received her Doctor of Osteopathic Medicine from the University of New England College of Osteopathic Medicine (UNE COM) in Biddeford, Maine. Dr. Mariano's past leadership roles include serving as Site Liaison at Maine General Medical Center Clinical Campus where she acted as a facilitator and student ambassador between the Office of Clinical Education and the then third-year students at UNE COM. She was also elected as the Class of 2021 Vice President of the Student Government Association at UNE COM. In 2021, Dr. Mariano was selected as the recipient of the Sauter Award of Graduate with Distinction, an honor sponsored by UNE COM Dean, for her demonstrated commitment to patient compassion and care. Claudia Mosquera Vasquez, MD, is a pediatric nephrology fellow physician at Nationwide Children's Hospital in Columbus, Ohio. Dr. Mosquera Vasquez also completed her Pediatrics residency at Nationwide and served as Chief Resident in Columbus. She received her Doctor of Medicine degree from Universidad Central de Venezuela, Escuela de Medicina Luis Razetti in Caracas, Venezuela. Dr. Mosquera Vasquez's leadership roles at Nationwide Children's Hospital include having served as co-chairperson of the Residency Diversity and Inclusion Coalition, membership on the Residency Recruitment Committee, and a pediatric residency interviewer. Her teaching and mentorship experience include serving as a curriculum developer of the Pediatric Equity and Advocacy Resident Learning Series (PEARLS). She has been recognized by her educators as a physician with true professionalism and strong commitment to leadership and peer advocacy. She has also been recognized with multiple awards including the Excellence in Research Award from her Pediatrics program. Bolatito Adeyeri is a third-year medical student at Baylor College of Medicine in Houston, Texas, having received her bachelor's degree in Kinesiology from the University of Houston. Ms. Adeyeri's leadership roles include serving as a representative on the Baylor College of Medicine Honor Council, a medical student representative on the Harris County Medical Society Health Care Quality Committee, and as Secretary of the Baylor Sports Medicine Interest Group. Nationally, she is involved in many activities with the American Medical Association including serving as the Region 3 Diversity, Equity, Inclusion, and Accessibility Chair and as a member of the AMA Medical Student Section House of Delegates Coordination Committee. Ms. Adeyeri is the recipient of the William Randolph Hearst Leadership Scholarship from the University of Houston Honors College and is a member of Phi Beta Kappa. Sujay Ratna is a second-year medical student at Icahn School of Medicine at Mount Sinai, having received his bachelor's degree in Biology from Rutgers University in New Jersey. Mr. Ratna's leadership roles include Vice President of Membership-Elect of the American Medical Student Association where he also serves on the National Executive Board and the AMSA Advocacy Task Force. Mr. Ratna is a member of Phi Beta Kappa and was selected as a finalist for the Truman Scholarship, a premier graduate fellowship for individuals interested in careers as public service leaders. "I want to give a heartfelt thank you to our retiring Board Members whose contributions have contributed to advancing NRMP's strategic goals and thought leadership," said NRMP President and CEO Donna L. Lamb, DHSc, MBA, BSN. "I would like to specifically acknowledge Dr. Steven Scheinman, former Chair of the NRMP Board, whose twelve years of service and contributions to the NRMP have been instrumental in helping to implement major initiatives such as the Supplemental Offer and Acceptance Program ® and collection of applicant demographic data." The newly elected Board Members replace five exceptional physicians and retiring Board Members: Steven Scheinman, MD, President and Dean Emeritus at Geisinger Commonwealth School of Medicine. A former Chair of the NRMP Board, Dr. Scheinman has served since July 2011. Ricardo Bello Boccardo, MD, MPH, Surgical Oncology Fellow at the Medical College of Wisconsin. Katherine Scribner, DO, Surgical Pathology Fellow at University of Southern California/LAC+USC Medical Center. Tiffany Morton, MD/MPH candidate at The Ohio State University College of Medicine and College of Public Health. Morgan Swanson, MD, PhD, Incoming PGY-1 resident in Pediatrics at the University of Iowa Hospitals and Clinics. The Main Match Process For applicants, the Main Residency Match process begins in the fall during the final year of medical school, when they apply to the residency programs of their choice. Throughout the fall and early winter, applicants interview with programs. From February to early March, applicants and program directors rank each other in order of true preference and submit the rank order lists to NRMP, which processes them using a computerized mathematical algorithm to match applicants with programs. Research on the NRMP algorithm was a basis for awarding The Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel in 2012. About NRMP The National Resident Matching Program® (NRMP®) is a private, non-profit organization established in 1952 at the request of medical students to provide an orderly and fair mechanism for matching the preferences of applicants for U.S. residency positions with the preferences of residency program directors. In addition to the annual Main Residency Match® for more than 48,000 registrants, the NRMP also conducts Fellowship Matches for more than 70 subspecialties through its Specialties Matching Service® (SMS®). To schedule an interview with NRMP President and CEO Donna L. Lamb, DHSc, contact [email protected]. SOURCE National Resident Matching Program